May 12, 2021 at 6:35AM
Canopy Growth (NASDAQ:CGC) released its fiscal 2020 third-quarter earnings report on Feb. 9. Its strong results for the period, which ended Dec. 31, helped drive its share price to a 52-week high of $56.50 the following day.
Since then, the stock price has gone downhill significantly. Last week, the Canopy Growth closed at just $25.26. Over the past month, it has fallen by 19%. Over the same period, the sector-benchmark
Horizons Marijuana Life Sciences ETF, declined by 15%.
The cannabis giant s next earnings report is due out on June 1, and what investors learn then will likely determine whether the stock s sell-off continues or reverses. But in the meantime, investors should ask themselves whether Canopy Growth s stock has fallen far enough that it s worth taking a chance on?
May 8, 2021 at 6:30AM
Are you looking for some quality pot stocks to add to your portfolio that aren t incredibly overpriced and could be due to post some strong numbers this year? Two stocks you won t want to ignore are
Harvest Health & Recreation (OTC:HRVSF). Not only are these companies doing well, but investing in them won t cost you a hefty premium they are trading at cheap levels compared to some of their peers.
Both of these stocks are also in great positions to take advantage of some hot new marijuana markets, and investing in them today could set you up for some strong returns in 2021.
May 4, 2021 at 10:46AM
Marijuana legalization in the U.S. could be years away from becoming a reality. However, that isn t stopping Canadian cannabis businesses from staking out positions beforehand. They want to be ready to go when the market opens up, and that is why there has been an uptick on the mergers and acquisitions (M&A) front of late.
Last week,
Valens (OTC:VLNCF) became the latest name to announce its entry into the U.S. market with the acquisition of Green Roads, a U.S. company that makes hemp-derived cannabidiol (CBD) products. Let s take a closer look at what it means for Valens, and for the industry in the U.S.
Author Bio
Sushree is a new member of the Fool family, keen on writing about the cannabis and healthcare sector and also has five years of experience writing on real estate, consumer sector, and macroeconomic topics. She holds a bachelor’s degree in business management, specializing in finance, and also a CFA Level 2 candidate. Being a fitness enthusiast and a creative person, when she isn t writing, she is either kick-boxing or painting.
Innovative Industrial Properties (NYSE:IIPR) is not a pure-play cannabis company. It is an REIT (real estate investment trust) that acquires properties from medical cannabis companies and leases them back. Investors are sometimes skeptical of putting their money in U.S. cannabis stocks, as the drug remains illegal at the federal level. Here, Innovative offers them a safer choice as it only offers real estate capital for the medical cannabis industry but has no direct involvement with cannabis. Hence, it is safe from t